☰
✕

Chordoma disease therapeutics market

Chordoma Disease Therapeutics Market, by Drug Class (Antimetabolites, Anthracycline, VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), by End User (Hospitals, Clinics, Oncology Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Request Free Sample
  • Jul 2023
  • CMI3979
  • 180 Pages
  • Excel & Pdf
  • Pharmaceutical

The global chordoma disease therapeutics market is estimated to be valued at US$ 6,029.3 million in 2023 and is expected to exhibit a CAGR of 6.9% during the forecast period (2023-2030).

Analysts’ Views on Global Chordoma Disease Therapeutics Market:

Increasing prevalence of and awareness about chordoma disease, rising geratic population, and new drugs releases and strategic efforts by prominent market competitors are favorably impacting the market's growth. The high prevalence of cancer, favorable health reimbursement, and increased awareness regarding cancer among people and clinicians is a major factor in the chordoma disease therapeutics market, thereby contributing to the market growth.

Figure 1. Global Chordoma Disease Therapeutics Market Share (%), By Drug Class, 2023

Global Chordoma Disease Therapeutics Market– Driver

Increasing prevalence of chordoma cancer

Increasing prevalence of chordoma cancer is expected to propel growth of the global chordoma disease therapeutics market over the forecast period. For instance, according to an article published in the World Health Organization, in February 2022, the age-standardized point prevalence and annual incidence rates of Cancer were 246.6 and 14.9 in 2021, which increased by 7.4% and 8.2% from 1990, respectively. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. As per the national orgniasation of rare disorders reported, the incidence of chordoma is estimated approximately 1 per 1,000,000 people. About 300 cases of chordoma are diagnosed in the U.S. each year.

Increasing drug approvals for chordoma treatment

Increasing drug approvals from regulatory authorities for the treatment of chordoma is expected to drive growth of the chordoma disease therapeutics market over the forecast period. For instance, in December 2022, MaxiVAX, a biotechnology company, developed a cancer vaccine comprising an immune boost agent released in situ by an engineered cell line and cancer autologous cells providing antigens. A Phase I trial with 25 patients with an advanced stage of cancer showed encouraging efficacy data and safety profile of the treatment. The  European union -funded MaxONCO project Phase II clinical trial evaluate this vaccine in 45 patients with head and neck cancer and in chordoma patients. The chordoma trial has been conducted in the EU and USA as an Investigational New Drug Programme that allows fast-track marketing of the drug in case of successful trial results.

Figure 2. Global Chordoma Disease Therapeutics Market Value (US$ Million), by Region, 2023

Global Chordoma Disease Therapeutics Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global chordoma disease therapeutics market over the forecast period. North America is estimated to hold 34.1% of the market share in 2023. The global chordoma disease therapeutics market is expected to witness significant growth in the coming years, driven by the high prevalence of cancer, favorable health reimbursement, and increased awareness, North America to emerge as the leading region for the chordoma disease therapeutics market. For instance, according to the press release in February 2020, by imaware, provides laboratory testing for wellness monitoring, informational, and educational use in North America, announced the launch of the At-Home Cancer Screening Test, designed by healthcare company Micro drop. The imaware test for cancer uses just a few drops of blood to detect unique biomarkers as well as two additional drugs to provide more comprehensive results. These kinds of developments in the healthcare system and rising health expenditures, as well as increased knowledge of advanced cancer treatments, are fueling the chordoma disease therapeutics market in North America.

Global Chordoma Disease Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global chordoma disease therapeutics market. The COVID-19 outbreak affected the market's growth adversely in its preliminary phase; however, the number of cancer patients increased, and so has the demand for the chordoma disease market. For instance, according to an article published in February 2022 on PubMed Central, “COVID-19 and Cancer Cross talk: Emerging Association, Therapeutic Options and Challenges”, explains that the management of cancer patients in the COVID-19 context is a difficult task in and of itself. Even though online consultations are advisable with patients who are having stable cancer.

Chordoma Disease Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 6,029.3 Mn
Historical Data for: 2018 to 2022 Forecast Period: 2023 to 2030
Forecast Period 2023 to 2030 CAGR: 6.9%  2030 Value Projection: US$ 9,648.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Antimetabolites, Anthracycline,VEGFR inhibitors, EGFR inhibitor, Others
  • By Treatment Type: Chemotherapy, Targeted Therapy, Radiation Therapy, Others
  • By End User: Hospitals, Clinics, oncology centers, others
Companies covered:

GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy’s Laboratories Ltd., Celgene Corporation, Eli Lilly and Company  ayer AG, Johnson & Johnson Services, Inc , Merck & Co., Inc., Optivus Proton Therapy, Inc, ProCure Treatment Centers, Inc., Varian Medical Systems, Inc. Amura Holdings Ltd., Catena pharmaceuticals Inc., Celldex Therapeutics , Eckert & Ziegler BEBIG, Infinity Pharmaceuticals, Inc, Medivir, Verdict Media Limited, Mylan N.V.
Growth Drivers:
  • Increasing prevalence of  chordoma cancer 
  • Increasing drug approvals for chordoma treatment
Restraints & Challenges:
  • Chemotherapeutic drugs approved for the treatment of chordoma are showing side effects.

Global Chordoma Disease Therapeutics Market Segmentation:

The Global chordoma disease therapeutics market report is segmented By Drug Class, By Treatment Type, By End User and Region.

By Drug Class, the market is segmented into antimetabolites, anthracycline, vegfr inhibitors, EGFR inhibitor, and others. Out of which, the  antimetabolites is expected to hold a dominant position in the global chordoma disease therapeutics market during the forecast period and this is attributed to awareness about chordoma disease.

By Treatment Type, the market is segmented into chemotherapy, targeted therapy, radiation therapy, and others. Out of which, the chemotherapy is expected to dominate the market over the forecast period and this is attributed to prompt treatment can lead to proper recovery.

By End User, the market is segmented into hospitals, clinics, oncology centers, and others. Out of which, hospitals is expected to dominate the market over the forecast period and this is attributed to prevention, diagnosis, multidisciplinary treatment, supportive care, research and education.

Among all the segmentations, the treatment type segment expected to dominate the market over the forecast period and this is attributed to the block tumour growth in  chordoma disease is which is expected boost the growth of chordoma disease therapeutics market over the forecast period.

Global Chordoma Disease Therapeutics Market Cross Sectional Analysis:

Key players are making chordoma disease therapeutics with proper drug treatment emerging economies is also expected to boost demand chordoma disease therapeutics market in North America region. For instance, in October 2020, Myriad Genetic Laboratories, Inc., a genetic testing and precision medicine company based in Salt Lake City, Utah, U.S., introduced Myriad's EGFR inhibitor treatment method from the Japanese Ministry of Health, Labor, and Welfare to be utilized as a partnered treatment.

Global Chordoma Disease Therapeutics Market: Key Developments

On May 31, 2023, Boehringer Ingelheim International, a pharmaceutical company, developed Afatinib dimaleate, a 4-anilinoquinazoline, antineoplastic agent. It is formulated as film coated tablets for oral route of administration. It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) tumors have epidermal growth factor receptor (EGFR) exon-19 deletions or exon-21 (L858R) substitution mutations as detected by an US FDA-approved test, indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic (including cytologically proven pleural effusion) adenocarcinoma of the lung with activating EGFR mutation(s).

In December 2020, Bavarian Nordic A/S, a integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines in Denmark, announced top-line results from a Phase 2 clinical study evaluating the targeted immunotherapy candidate, BN-Brachyury in the treatment of advanced chordoma, a rare cancer occurring in the base of the skull and spine. While the study failed to meet its primary endpoint, it provided evidence of clinical activity.

On June 1, 2023, Myriad Genetics, Inc., is a company of genetic testing and precision medicine, launched new studies and expansion of its Precise Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO).

On March 22, 2023, F. Hoffmann-La Roche Ltd (Roche), a biotechnology company that develops drugs and diagnostics to treat major diseases, announced that it has entered into a collaboration with Eli Lilly and Company is pharmaceutical company headquartered in U.S. to support the development of Roche’s Elecsys chordoma disease therapeutics.

In March 2022, Invitae, a medical genetics company, announced full access to its Personalized Cancer Monitoring (PCMTM) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors. Invitae PCM uses a novel set of personalized assays based on a patient's tumor to detect circulating tumor DNA (ctDNA) in blood, offering the ability to perform risk stratification, response assessment to treatment and detection of cancer recurrence, based on recent studies.

Global Chordoma Disease Therapeutics Market: Key Trends

Application of biomarker test for diagnosing chordoma disease

Application of biomarker test for diagnosing chordoma disease is expected to propel growth of the global chordoma disease therapeutics market over the forecast period. Major players in the market are focused on adopting partnership strategies to expand its product portfolio. Presently, there is no drugs available for the diagnosis of chordoma disease. However, anti–cyclic citrullinated peptide (anti–CCP) antibodies test require more refinement to improve its clinical utility. For instance, in March 2020, WorldCare Clinical, LLC, an independent contract research organization offering imaging in clinical trials, partnered with Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immuno-therapeutics, to offer imaging service following U.S. FDA approval of Navidea’s cancer diagnostic. Navidea’s strategy is to deliver novel products and advancing the company’s pipeline through global partnering with WorldCare Clinical, LLC.

Global Chordoma Disease Therapeutics Market: Restraint

Chemotherapeutic drugs approved for the treatment of chordoma are Showing side effects

Chemotherapeutic drugs approved for the treatment of chordoma are not always effective and have several side effects such as nausea, headache, and hair loss is expected to hamper the growth of the global chordoma disease therapeutics market. For instance, according to an article published in the National library of medicine, on February 27, 2023, reported antimetabolites have a sevral side effects such as dose-limiting myelosuppression. Toxic levels of 5-fluorouracil occur in patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency or drug overdose. This lead to cardiac dysfunction, colitis, neutropenia, and encephalopathy.

Key market Players are focusing on Safety and efficacy of drugs.

Global Chordoma Disease Therapeutics Market- Key Players

Major players operating in the global chordoma disease therapeutics market include GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy’s Laboratories Ltd., Celgene Corporation, Eli Lilly and Company  ayer AG, Johnson & Johnson Services, Inc , Merck & Co., Inc., Optivus Proton Therapy, Inc, ProCure Treatment Centers, Inc., Varian Medical Systems, Inc. Amura Holdings Ltd., Catena pharmaceuticals Inc., Celldex Therapeutics, Eckert & Ziegler BEBIG, Infinity Pharmaceuticals, Inc, Medivir, Verdict Media Limited,  and Mylan N.V.

Global Chordoma Disease Therapeutics Market– Definition

Chordoma is a rare type of cancer, which occurs in the spine region or from the base of the skull to the tailbone. Chordoma is included in a group of malignant bone and soft tissue tumors called sarcomas. Chordomas are the most common tumor of the sacrum and cervical spine. Chordoma tumors can press the spine, brain, and nerves as they grow causing nerve problems such as tingling, numbness, weakness, lack of bladder or bowel control, sexual dysfunction, vision problems, endocrine problems, and swallowing difficulties.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Treatment Type
      • Market Snippet, By End User
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Recent Drug Launches
    • Epidemiology
    • Merger, Acquisition, and Collaborations
    • Regulatory Scenario
    • Key Developments
    • PEST Analysis
  4. Global Chordoma Disease Therapeutics  Market–COVID-19 Impact Analysis
      • Economic Impact
      • COVID-19 Epidemiology
      • Impact on Supply and Demand
  5. Global Chordoma Disease Therapeutics Market, By Drug Class, 2018 – 2030 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019–2030
      • Segment Trends
    • Antimetabolites
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
      • Segment Trends
    • Anthracycline
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
      • Segment Trends
    • VEGFR inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
      • Segment Trends
    • EGFR inhibitor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
      • Segment Trends
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
      • Segment Trends
  6. Global Chordoma Disease Therapeutics  Market, By Treatment Type, 2018 – 2030 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019–2030
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
    • Targeted Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
    • Radiation Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
  7. Global Chordoma Disease Therapeutics  Market, By End User, 2018 – 2030 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019–2030
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
    • Oncology centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
  8. Global Chordoma Disease Therapeutics  Market, By Regions, 2018 – 2030 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2019–2030
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, By Drug Class, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, By Drug Class, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Drug Class, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, By Drug Class, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, By Drug Class, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Drug Class, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Company Profiles
      • GlaxoSmithKline Plc*
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Bavarian Nordic A/S
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Boehringer Ingelheim International GmbH
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Sanofi SA
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Astellas Pharma Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • AstraZeneca plc
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Bristol-Myers Squibb and Company
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Dr. Reddy’s Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Celgene Corporation
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Eli Lilly and Company 
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      •  Johnson & Johnson Services, Inc
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Optivus Proton Therapy, Inc
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • ProCure Treatment Centers, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Varian Medical Systems, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Amura Holdings Ltd.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Catena pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Celldex Therapeutics
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Eckert & Ziegler BEBIG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Infinity Pharmaceuticals, Inc
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Medivir
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      • Verdict Media Limited
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
      •  Mylan N.V.Invitae Corporation
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 30 market data tables and 24 figures on “Chordoma Disease Therapeutics Market – Global forecast to 2030

Detailed Segmentation:

  • Global Chordoma Disease Therapeutics Market, By Drug Class:
    • Antimetabolites
    • Anthracycline
    • VEGFR inhibitors
    • EGFR inhibitor
    • Others
  • Global Chordoma Disease Therapeutics Market, By Treatment Type:
    • Chemotherapy
    • Targeted Therapy
    • Radiation Therapy
    • Others
  • Global Chordoma Disease Therapeutics Market, By End User:
    • Hospitals
    • Clinics
    • oncology centers
    • others
  • Global Chordoma Disease Therapeutics, By Region:
    • North America
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR inhibitors
        • EGFR inhibitor
        • Others
      • By Treatment Type:
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • oncology centers
        • others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR inhibitors
        • EGFR inhibitor
        • Others
      • By Treatment Type:
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • oncology centers
        • others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR inhibitors
        • EGFR inhibitor
        • Others
      • By Treatment Type:
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • oncology centers
        • others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR inhibitors
        • EGFR inhibitor
        • Others
      • By Treatment Type:
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • oncology centers
        • others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR inhibitors
        • EGFR inhibitor
        • Others
      • By Treatment Type:
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • oncology centers
        • others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Antimetabolites
        • Anthracycline
        • VEGFR inhibitors
        • EGFR inhibitor
        • Others
      • By Treatment Type:
        • Chemotherapy
        • Targeted Therapy
        • Radiation Therapy
        • Others
      • By End User:
        • Hospitals
        • Clinics
        • oncology centers
        • others
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global chordoma disease therapeutics market during the forecast period (2023-2030)?

The global chordoma disease therapeutics market is estimated to be valued at US$ 6,029.3 million in 2023 and is expected to exhibit a CAGR of 6.9% between 2023 and 2030.

What are the major factors driving the market growth?

Increasing prevalence of chordoma cancer and increasing drug approvals for chordoma treatment is expected to drive the market growth.

Which is the leading Drug Class segment in the market?

Antimetabolites is the leading segment in the market.

What are the key factors hampering the growth of the market?

Chemotherapeutic drugs approved for the treatment of chordoma are showing side effcts  expected to hinder the market over the forecast period.

Which are the major players operating in the market?

Major Players including GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy’s Laboratories Ltd., Celgene Corporation, Eli Lilly and Company  ayer AG, Johnson & Johnson Services, Inc , Merck & Co., Inc., Optivus Proton Therapy, Inc, ProCure Treatment Centers, Inc., Varian Medical Systems, Inc. Amura Holdings Ltd., Catena pharmaceuticals Inc., Celldex Therapeutics , Eckert & Ziegler BEBIG, Infinity Pharmaceuticals, Inc, Medivir, Verdict Media Limited,  and Mylan N.V.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now